Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

We are advancing programs in women’s health, including endometriosis-associated pain and egg maturation in assisted reproduction, including in vitro fertilization (IVF), and the prevention of pregnancy.

Over time, we intend to expand our development pipeline to include potential treatments for women's health.

FDA Approved Drugs: ORGOVYX (relugolix 120 mg), MYFEMBREE (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg)

Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
September 9, 2021
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
September 1, 2021
Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
August 12, 2021
Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
Events

SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.INS - XBRL INSTANCE DOCUMENT

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.INS - XBRL INSTANCE DOCUMENT